Insiders Updates
Spero Therapeutics Inc’s latest rating changes from various analysts
Spero Therapeutics Inc’s recent filing unveils that its CFO & CBO Rajavelu Esther unloaded Company’s shares for reported $30590.0 on
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.